Page last updated: 2024-12-09

nbd 556

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1570601
CHEMBL ID254781
SCHEMBL ID1287379
MeSH IDM0503116

Synonyms (34)

Synonym
CBMICRO_035139
n'-(4-chlorophenyl)-n-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide
HY-76648
n1-(4-chlorophenyl)-n2-(2,2,6,6-tetramethylpiperidin-4-yl)oxalamide
n-(4-chlorophenyl)-n''-(2,2,6,6-tetramethylpiperidin-4-yl)-oxalamide
bdbm50333241
ethanediamide, n-(4-chlorophenyl)-n'-(2,2,6,6-tetramethyl-4-piperidinyl)-
n-(4-chlorophenyl)-n'-(2,2,6,6-tetramethyl-4-piperidyl)oxamide
nbd-556
BIM-0034951.P001
STK042210
n-(4-chlorophenyl)-n'-(2,2,6,6-tetramethylpiperidin-4-yl)ethanediamide
CHEMBL254781 ,
AKOS000339835
03g ,
CS-0526
BRD-K59747209-001-02-6
BRD-K59747209-001-01-8
333353-44-9
SCHEMBL1287379
DTXSID20364454
n1-(4-chlorophenyl)-n2-(2,2,6,6-tetramethyl-4-piperidinyl)ethanediamide
nbd 556
J-019150
NCGC00378746-02
n-(4-chlorophenyl)-n'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamide
mfcd00469538
N1090
Q27449813
NCGC00378746-04
n'-(4-chlorophenyl)-n-(2,2,6,6-tetramethylpiperidin-4-yl)ethanediamide
EN300-221866
AS-75693
Z57324495

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Particularly, BMS-378806 and its derivatives are newly identified class of orally bioavailable HIV-1 inhibitors that interfere gp120-CD4 interaction."( Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
De Clercq, E; Huang, B; Liu, T; Liu, X; Zhan, P, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 Human immunodeficiency virus 1IC50 (µMol)1.87750.00352.70228.7000AID1624241; AID1756242; AID1756243; AID1878228
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)250.00000.00011.076810.0000AID1769793; AID1877036
Env polyprotein Human immunodeficiency virus 1IC50 (µMol)0.61000.61000.61000.6100AID1163347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Envelope glycoprotein gp160Human immunodeficiency virus type 1 (isolate YU2)Kd3.70003.70003.70003.7000AID549734
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID549733Inhibition of HIV1 YU2 gp120 binding to CD4 expressing Cf2Th-CD4/CCR5 cells assessed as inhibition of viral infection after 48 hrs2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening.
AID629095Induction of gp120 conformational change in R5 tropic Human immunodeficiency virus 1 subtype B isolate JR-FL infected in human PM1 cells assessed as binding of anti-HIV1 mAb 4C11 measuring mean fluorescence intensity at 100 uM preincubated for 15 mins by 2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID549734Binding affinity to HIV1 YU2 gp120 by isothermal titration calorimetry assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening.
AID629098Selectivity index, ratio of CC50 for mock-infected human PM1 cells expressing CCR5 to IC50 for R5 tropic HIV1 YTA infected in human TZM-bl cells2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID1624242Cytotoxicity against human TZM-b1 cells assessed as reduction in cell viability by CCK8 assay2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.
AID676297Cytotoxicity against human MT2 cells after 4 days by XTT assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.
AID451775Antiviral activity against HIV1 fTOI primary isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID1605162Antiviral activity against CD4-dependent pseudovirus HIV1 ADA infected in dog Cf2Th-CCR5 cells preincubated for 30 min followed by viral infection and measured after 48 hrs by luciferase based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.
AID1769793Inhibition of recombinant HIV1 reverse transcriptase by colorimetric assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.
AID704279Antiviral activity against HIV-1 clade B Env pseudovirus assessed as geometric mean titer for virus neutralization to infect human TZM-bl cells by luciferase assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.
AID451772Inhibition of HIV1 gp120 binding to CD42010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID516487Antiviral activity against HIV1 isolate 89.6 infected in human PM1 cells expressing CCR5 assessed as protection against virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID763078Cytotoxicity against CCR5-expressing human PM1 cells assessed as reduction of cell viability after 7 days by WST8 assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.
AID676295Inhibition of X4-tropic HIV1 3B gp120-mediated entry into human MT2 cells assessed as Inhibition of p24 production incubated overnight followed by compound wash-out measured after 4 days post-infection by multi-cycle neutralization assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.
AID1756244Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability by Cell Titer-Glo assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors.
AID1271999Induction of conformational change in R5-tropic HIV1 cYTA48P gp120 infected in human PM1 cells assessed as increase in binding affinity to monoclonal antibody 4C11 at 100 uM after 15 mins by FACS analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.
AID451778Inhibition of gp120 binding to CD4 in HIV1 JR-FL infected human PM1 cells assessed as binding of anti-envelope CD4-induced monoclonal antibody 4C11 to envelope expressing cell surface at 100 uM pretreated 15 mins before 4C11 addition by FACS analysis2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID516489Displacement of [125I]-SDF-1-alpha from CXCR4 expressed in CHO cells2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID1442773Inhibition of recombinant CD4-dependent HIV1 ADA pseudovirus gp120-mediated viral entry in CD4-negative Cf2Th-CCR5 cells preincubated for 30 mins followed by addition of cells measured after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1878228CD4 mimetic activity at gp120 in HIV-1 KP-5mvcR infected in human TZM-bl cells assessed as inhibition of viral entry by measuring reduction in RLU by single round assay2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors.
AID1756243Inhibition of HIV1 KP-5mp1 gp120 interaction with CD4 human TZM-bl cells assessed as decrease in viral entry by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors.
AID1716243Inhibition of HIV1 gp120-mediated cell-cell fusion between viral envelope expressing in human HL2/3 cells to CD4/CCR5 receptor expressing in human TZM-bl cells after 1 hr by luciferase reporter gene assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1877040Potency index, ratio of test compound EC50 to NBD-14189 EC50 for antiviral activity against HIV1 pseudovirus infected in human TZM-bl cells preincubated with virus for 30 mins followed by cell infection and measured after 3 days by luciferase assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID704292Inhibition of recombinant HIV-1 YU2 envelope glycoprotein-120 assessed as inhibition of viral entry in canine Cf2Th cells expressing CD4/CCR5 after 2 to 4 hrs by luciferase activity based luminescence assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.
AID516486Antiviral activity against HIV1 3B infected in human PM1 cells expressing CCR5 assessed as protection against virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID1877039Potency index, ratio of test compound IC50 to NBD-14189 IC50 for inhibition of recombinant HIV-1 reverse transcriptase incubated for 2 hrs by colorimetric assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID1871996Antiviral activity against HIV-1 pseudotyped virus expressing HXB-2 Env proteins infected in human TZM-bl cells assessed as inhibition of viral entry preincubated for 30 mins followed by infection with cells and measured after 3 days by luciferase based a2022European journal of medicinal chemistry, Feb-05, Volume: 229Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
AID1442772Inhibition of HIV1 HXB2 gp120-mediated cell to cell fusion using human MAGI-CCR5 cells as indicator cells and Env/Tat-expressing HL2/3 cells as effector cells preincubated with MAGI-CCR5 cells for 1 hr followed by HL2/3 cells addition by beta-galactosidas2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID549735Antiviral activity against recombinant HIV1 YU2 in Cf2Th-CCR5 cells assessed as viral infectivity by luciferase assasy relative to JRC-II-1912011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening.
AID676300Cytotoxicity against human TZM-b1 cells at >60 uM after 3 days by XTT assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.
AID516483Antiviral activity against HIV1 MNA infected in human PM1 cells expressing CCR5 assessed as protection against virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID1878229Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability by CellTiter-Glo 2.0 assay2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors.
AID1418638Cytotoxicity against human PM1 cells harboring CCR5 co-receptor by WST-8 assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Flexibility of small molecular CD4 mimics as HIV entry inhibitors.
AID1871993Antiviral activity against HIV-1 IIIB infected in human MT2 cells assessed as reduction in p24 antigen level incubated for 1 hr by ELISA2022European journal of medicinal chemistry, Feb-05, Volume: 229Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
AID1878230Aqueous solubility of the compound in PBS at pH 7.4 at 25 degC2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors.
AID1442776Inhibition of HIV1 reverse transcriptase by colorimetric assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1769795Mimetic activity of CD4 at gp120 in HIV-1 ADA infected in CD4-negative dog Cf2Th-CCR5 cells assessed as agonism of viral entry by measuring enhancement of viral infection at 20 to 60 uM pretreated for 30 mins before viral infection and incubated for 48 hr2021European journal of medicinal chemistry, Nov-15, Volume: 224Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.
AID1418637Antiviral activity against HIV1 cYTA48P infected in PM1/CCR5 cells by single round assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Flexibility of small molecular CD4 mimics as HIV entry inhibitors.
AID516484Cytotoxicity against human PM1 cells expressing CCR5 by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID1877037Antiviral activity against HIV-1 pseudovirus infected in human TZM-bl cells preincubated with virus for 30 mins followed by cell infection and measured after 3 days by luciferase assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID1871998Selectivity index, ratio of CC50 for Cytotoxicity against human TZM-bl cells to EC50 for antiviral activity against HIV-1 pseudotyped virus expressing HXB-2 Env proteins infected in human TZM-bl cells2022European journal of medicinal chemistry, Feb-05, Volume: 229Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
AID1877038Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 3 days by XTT assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID704278Antiviral activity against HIV-1 clade C Env pseudovirus assessed as geometric mean titer for virus neutralization to infect human TZM-bl cells by luciferase assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.
AID1877036Inhibition of recombinant HIV-1 reverse transcriptase incubated for 2 hrs by colorimetric assay2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID1163347Inhibition of HIV-1 isolate YTA48P HIV-1 gp1202014European journal of medicinal chemistry, Oct-30, Volume: 86Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
AID1871994Cytotoxicity against human MT2 cells assessed as reduction in cell viability incubated for 4 days by XTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
AID676296Cytotoxicity against human TZM-b1 cells after 3 days by XTT assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.
AID1271997Antiviral activity against R5-tropic HIV1 cYTA48P infected in TZM-bl cells by single round assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.
AID1271998Cytotoxicity against mock-infected human PM1 cells expressing CCR5 by WST method2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.
AID516492Selectivity index, ratio of CC50 for human PM1 cells expressing CCR5 to IC50 for HIV1 MNA2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID451774Antiviral activity against HIV1 89.6 laboratory isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID516485Inhibition of CD4-induced monoclonal antibody 4C11 binding to HIV1 MNA infected in human PM1 cells expressing CCR5 at 100 uM after 15 mins by FACS analysis (Rvb = 27.60)2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID629100Antiviral activity against R5 tropic HIV1 YTA infected in human TZM-bl cells assessed as beta-galactosidase activity preincubated for 15 mins before infection measured after 2 days by single-round assay using luminometry2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID1624245Binding affinity to HIV1 cYTA48P envelope glycoprotein gp120 infected in human TZM-b1 cells assessed as induction of conformational changes by measuring combination index at 15:1 ratio of test compound to KD-247 measured after 48 hrs2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.
AID1769790Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 3 days by XTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.
AID763079Antiviral activity against Human immunodeficiency virus 1 R5 primary isolate YTA48P infected in CCR5-expressing human PM1 cells assessed as inhibition of virus-induced cytopathogenicity after 7 days by WST8 assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.
AID1716244Induction viral infection in pseudovirus HIV1 ADA infected in dog Cf2Th-CCR5 cells incubated for overnight followed by pretreated for 30 mins and added to cells measured after 48 hrs by luciferase-based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID516491Cytotoxicity against human MT2 cells by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID1624241Binding affinity to HIV1 cYTA48P envelope glycoprotein gp120 infected in human TZM-b1 cells assessed as induction of conformational changes measured after 48 hrs2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.
AID451777Cytotoxicity against mock-infected CCR5 expressing human PM1 cells by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID451773Antiviral activity against HIV1 3B laboratory isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID1605169Cytotoxicity against dog Cf2Th-CCR5 cells infected with CD4-dependent pseudovirus HIV1 ADA incubated for 8 hrs by MTS assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.
AID318580Binding affinity to HIV glycoprotein 1202007Nature, Dec-13, Volume: 450, Issue:7172
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
AID451776Antiviral activity against HIV1 KYAG primary isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID629096Antiviral activity against HIV1 infected in human PM1 cells expressing CCR5 assessed as inhibition of virus-induced cytopathogenicity by multi-round assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID516488Antiviral activity against HIV1 MTA infected in human PM1 cells expressing CCR5 assessed as protection against virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID516490Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID1769788Inhibition of gp120 in HIV-1 NL4-3 HXB-2-Luc pseudotyped virus infected in human TZM-bl cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based single cycle infection assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.
AID1716245Cytotoxicity against dog Cf2Th-CCR5 cells assessed as reduction in cell viability incubated for 48 hrs by XTT assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID704285Inhibition of ampotrophic murine leukemia virus envelope glycoprotein assessed as inhibition of viral entry in human 293T cells after 2 to 4 hrs by luciferase activity based luminescence assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.
AID1871995Selectivity index, ratio of CC50 for cytotoxicity against human MT2 cells to EC50 for antiviral activity against HIV-1 IIIB infected in human MT2 cells2022European journal of medicinal chemistry, Feb-05, Volume: 229Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
AID629099Cytotoxicity against mock-infected human PM1 cells expressing CCR5 by WST-8 assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID1418639Induction of conformational changes in HIV1 cYTA48P envelope glycoprotein gp120 infected in PM1/CCR5 cells assessed as mean fluorescence intensity using CD4i monoclonal antibody 4C11 at 100 uM after 15 mins by FACS analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Flexibility of small molecular CD4 mimics as HIV entry inhibitors.
AID676294Inhibition of X4-tropic HIV1 HXB2 gp120-mediated entry into human TZM-b1 cells expressing CD4,CXCR4,CCR5,luciferase and beta-galactosidase after 3 days by single cycle neutralization assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.
AID704281Binding affinity to HIV-1 YU2 gp120 at 80 to 130 uM by VP-ITC analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.
AID1871997Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 3 days by XTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
AID1756242Inhibition of HIV1 KP-5mvcR gp120 interaction with CD4 in human TZM-bl cells assessed as decrease in viral entry by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors.
AID1769796Cytotoxicity against CD4-negative dog Cf2Th-CCR5 cells assessed as reduction in cell viability incubated for 3 days by XTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.
AID1624243Aqueous solubility of the compound in phosphate buffered saline2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.17)29.6817
2010's14 (58.33)24.3611
2020's9 (37.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.24 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]